As Chief Technology Officer, Christina Yi leads the manufacturing, quality, supply chain, and technical operations functions for the Company. Ms. Yi is an accomplished executive who brings over 25 years of technical and operations leadership experience for both emerging public biotechnology companies as well as large multinational biopharma organizations. She previously served as the Chief Operations Officer at Provention Bio, Inc., which was acquired by Sanofi in 2023. During her tenure at Provention, she played a critical role in the achievement of U.S. Food and Drug Administration approval and subsequent commercial launch of Tzield™ (teplizumab-mzwv), a first-in-class therapy for type 1 diabetes. Prior to Provention she served as the Chief Operating Officer at Vaxxinity and Chief Operations Officer at Dendreon Pharmaceuticals LLC. Earlier in her career, she held roles of increasing responsibility at Amgen in Quality for three commercially successful products.

Ms. Yi obtained her B.S. in Cell and Molecular Biology from the University of Washington.